RYBOQUIN Trademark

Trademark Overview

On Thursday, August 25, 2016, a trademark application was filed for RYBOQUIN with the United States Patent and Trademark Office. The USPTO has given the RYBOQUIN trademark a serial number of 79195519. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, April 26, 2024. This trademark is owned by Ryboquin Company Limited. The RYBOQUIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, ligase inhibitors for the treatment of cancer
ryboquin

General Information

Serial Number79195519
Word MarkRYBOQUIN
Filing DateThursday, August 25, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, April 26, 2024
Registration Number5303812
Registration DateTuesday, October 10, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 25, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, ligase inhibitors for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, April 26, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRyboquin Company Limited
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressGB
Party NameRyboquin Company Limited
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressGB
Party NameRyboquin Company Limited
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressGB

Trademark Events

Event DateEvent Description
Thursday, November 3, 2016SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Friday, November 4, 2016LIMITATION FROM ORIGINAL APPLICATION ENTERED
Monday, November 7, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 11, 2016APPLICATION FILING RECEIPT MAILED
Tuesday, December 6, 2016ASSIGNED TO EXAMINER
Friday, December 9, 2016NON-FINAL ACTION WRITTEN
Saturday, December 10, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, December 12, 2016REFUSAL PROCESSED BY MPU
Monday, December 12, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, February 3, 2017REFUSAL PROCESSED BY IB
Sunday, June 11, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, June 11, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, June 11, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 12, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 13, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 5, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 25, 2017PUBLISHED FOR OPPOSITION
Tuesday, July 25, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 10, 2017REGISTERED-PRINCIPAL REGISTER
Friday, November 17, 2017TOTAL INVALIDATION PROCESSED BY THE IB
Wednesday, January 10, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, January 23, 2018FINAL DISPOSITION PROCESSED
Tuesday, January 23, 2018FINAL DISPOSITION NOTICE SENT TO IB
Monday, April 16, 2018IRREGULARITY ON FINAL DECISION RECEIVED FROM IB
Wednesday, May 2, 2018IRREGULARITY FROM IB EXAMINED BY MPU
Friday, May 11, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, April 24, 2019NEW REPRESENTATIVE AT IB RECEIVED
Monday, March 2, 2020INTERNATIONAL REGISTRATION RENEWED
Monday, October 10, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, April 26, 2024CANCELLED SECTION 71
Friday, December 27, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Tuesday, April 23, 2024NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

ryboquin treatment cancer inhibitors ligase preparations namely pharmaceutical